1
|
Cheze S, Quittet P, Adoue D, Viallard J, Sève P, Bonnotte B, Laribi K, Tardy S, Henique H, Graveleau J, Hacini M, Santagostino A, Aroichane M, Leclerc-Teffahi S, Niarra R, Guillemin S, Malatesta A, Michel M. Étude observationnelle prospective sur les Patients attEints de Purpura Thrombopénique Idiopathique (PTI) traités par des agonisTEs des R-TPO (ARTPO) : Eltrombopag et Romiplostim (Étude PEPITE). Rev Med Interne 2022. [DOI: 10.1016/j.revmed.2022.10.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
2
|
Parreau S, Bouquet R, Dumonteil S, Nuccio F, Madaule S, Guilpain P, Bienvenu B, Adoue D, Hachulla E, Sailler L, Hatron P, Palat S, Gondran G, Bezanahary H, Liozon E, Doussinaud A, Duchesne M, Ly K, Fauchais A, Magy L. Douleur neuropathique avec conduction nerveuse normale au cours du syndrome de Sjögren : étude histologique. Rev Med Interne 2022. [DOI: 10.1016/j.revmed.2022.10.111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
3
|
Bories E, De Almeida S, Porel T, Alric L, Astudillo L, Gaches F, Michaud M, Catros F, Prevot G, Sailler L, Adoue D, Lairez O, Pugnet G. Épidémiologie descriptive de l’atteinte cardiaque sévère dans la sclérodermie systémique : étude rétrospective bicentrique sur 459 patients. Rev Med Interne 2022. [DOI: 10.1016/j.revmed.2022.03.261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
4
|
De Almeida Chaves S, Benedicte P, Porel T, Bories E, Adoue D, Astudillo L, Alric L, Huart A, Michaud M, Ribes D, Prevot G, Sailler L, Gaches F, Pugnet G. AB0651 Clinical Impact and Prognosis of cryoglobulinemia and cryofibrinogenemia in Systemic Sclerosis. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundSystemic sclerosis (SSc) is reported to be a secondary cause of cryoglobulinemia as well as cryofibrinogenemia. However, prevalence, clinical implication and associated pronostic of cryoprecipitates in SSc are unknown.ObjectivesTo describe the prevalence, the phenotype and evaluate the prognosis of cryoglobulinemia and/or cryofibrinogenemia associated with systemic sclerosis.MethodsWe included all adult (≥18 years) consecutive SSc patients from the Systemic Scleroderma Toulouse Cohort (SSTC) [1] for whom a cryoglobulin and/or cryofibrinogen measurement was carried out at the immunology laboratory of the Toulouse University Hospital between June 1, 2005 and May 31, 2018 and at least one follow-up visit. We compared SSc-patients characteristics’ with and without cryoglobulinemia > 50 mg/l and with and without cryofibrinogenemia. Survival analysis based on presence of cryoglobulin cryofibrinogen was performed using the Kaplan-Meier method. Univariable and multivariable Cox proportional hazards models (ascending step-by-step method) were used to determine baseline variables associated with cryoglobulin or cryofibrinogen presence.Results166 patients were included in the study. 74.6% of patients were women, with a average age at diagnosis of 51.2 years-old. 24% were diffuse cutaneous subtypes and 71.6% limited cutaneous subtypes. Anti-centromere and anti-Scl70 were respectively positive in 44.5% and 21.6% of cases. All these patients were assessed for cryoglobulin detection and 75 cryofibrinogen detection in serum. 43.3% had a cryoglobulinemia >50 mg/l. 46.6% had cryofibrinogenemia. Patients with cryoglobulinemia >50 mg had more cardiac diastolic involvement (22.8% vs. 5.1% p=0.0395). In the multivariate analysis, diastolic involvement (HR=6.23; p=0.0331) was an independent predictor of cryoglobulin >50 mg/l. Survival at 10 years was better for patients with cryoglobulinemia >50 mg/l (log-rank 0.0363) (Figure 1). Survival at 5 and 10 years was 97.6% and 88.8% respectively in patients with cryoglobulinemia >50 mg/l versus 91.9% and 78.4% in patients with cryoglobulinemia <50 mg/l. In cox regression model adjusted for gender, age and type of systemic sclerosis, cryoglobulin >50 mg/l was negatively associated with mortality (HR: 0.09; p=0.03). The presence of cryofibrinogenemia was not associated with any clinical, biological or morphological features. In the multivariate analysis, no variable was predictive of the presence of cryofibrinogenemia in patients with SSc. The presence of cryofibrinogenemia had no influence on the mortality of these patients.ConclusionIn SSc patients, the presence of cryoglobulin >50 mg/l is an independent predictive factor of cardiac diastolic involvement and is associated with a better survival. However, cryofibrinogenemia does not influence clinical phenotype or impact mortality in SSc patients.References[1]De Almeida Chaves S, Porel T, Mounié M, Alric L, Astudillo L et al. Sine scleroderma, limited cutaneous, and diffused cutaneous systemic sclerosis survival and predictors of mortality. Arthritis Res Ther. 2021 Dec 7;23(1):295. doi: 10.1186/s13075-021-02672-y.Disclosure of InterestsNone declared
Collapse
|
5
|
De Almeida Chaves S, Puissant B, Porel T, Bories E, Adoue D, Astudillo L, Alric L, Huart A, Michaud M, Ribes D, Prevot G, Sailler L, Gaches F, Pugnet G. Impact clinique et pronostique d’une cryoglobulinémie et d’une cryofibrinogénémie au cours de la sclérodermie systémique. Rev Med Interne 2022. [DOI: 10.1016/j.revmed.2022.03.254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
6
|
Bories E, DE Almeida Chaves S, Porel T, Alric L, Astudillo L, Gaches F, Michaud M, Catros F, Prevot G, Sailler L, Adoue D, Lairez O, Pugnet G. POS0884 DESCRIPTIVE EPIDEMIOLOGY OF SEVERE CARDIAC INVOLVEMENT IN SYSTEMIC SCLEROSIS: A BICENTRIC RETROSPECTIVE STUDY ON 459 PATIENTS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2842] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundThe prevalence of cardiac involvement in systemic sclerosis (SSc) varies in the literature between 3% and 44% and represents a leading cause of mortality in this disease. The incidence of severe cardiac involvement and the factors associated with the occurrence of severe cardiac involvement are not known in the literature.ObjectivesThe objective of this study was to evaluate the incidence, prognosis and factors associated with the occurrence of severe cardiac involvement during SSc course.MethodsWe conducted a retrospective, bi-centric study from January 1, 1966 to December 31, 2018. The patients included had a diagnosis of SS according to the ACR/EULAR 2013 criteria. The primary endpoint was the occurrence of severe cardiac involvement. Cardiac involvement was defined by the presence of at least one of the following elements: death of cardiovascular origin, left ventricular ejection fraction less than or equal to 50%, abnormality of at least 3 measurement parameters of diastolic function, global longitudinal strain less than or equal to 18 in absolute value, ventricular tachycardia, ventricular extrasystoles requiring intervention or elevated troponin. Patients with associated myositis and whose only criterion for cardiac involvement was elevated troponin were not included in the group with cardiac involvement. Severe cardiac involvement was defined by the occurrence of hospitalization for cardiovascular reasons or by death of cardiovascular origin. Univariable and multivariable Cox proportional hazards models were used to determine variables associated with severe cardiac involvement occurrence. Survival analysis was performed using the Kaplan-Meier method with comparisons performed using the log rank test.ResultsFour hundred and fifty-nine patients with SSc were included and were followed for a median of 7.1 years [3.1; 13.3]. The median age of our population was 54 years old. There were 81% of women, 77% of patients had limited cutaneous SSc, 15% diffuse cutaneous SSc and 8% SSc sine scleroderma. Of the 459 patients, 105 (23%) had cardiac involvement and 56 (12%) severe cardiac involvement. The incidence of severe cardiac involvement was 2.42 per 100 patient years. Ninety-six hospitalizations were recorded, including 40 (42%) for acute heart failure, 19 (20%) for arrhythmia, 5 (5%) for acute pericarditis, 6 (6%) for acute myocarditis and 14 (15 %) for coronary artery disease (acute coronary syndrome, myocardial infarction or coronary revascularization). The independent factors associated with severe cardiac involvement in SSc were age over 54 years at SSc-diagnosis (OR = 3.21 95% CI [1.73; 5.95], p < 0.001), the presence of myositis (OR = 5.01 95% CI [1.89; 13.28], p = 0.001), pericardial involvement (OR = 3.79 95% CI [2.05; 7.03]; p < 0.001) or scleroderma renal crisis (OR = 4.72 95% CI [2.05; 10.92], p < 0.001). The survival rate of patients with severe cardiac involvement was 70% at 5 years and 53% at 10 years. Patients with severe cardiac involvement had a mortality risk three times greater than patients without severe cardiac involvement, HR = 3.1 (95% CI [1.7; 5.7], p<0.0001) (Figure 1). Pericardial involvement was an independent risk factor for mortality, HR = 2.0 (95% CI [1.02; 4.0], p=0.04).Figure 1.Survival of patients with severe cardiac involvement of systemic scleroderma. HR: Hazard ratio; 95% CI: 95% Confidence interval; Nb at risk: Number at riskConclusionWe need to focus our clinical attention on diagnosing and manage cardiac involvement in SSc, as severe cardiac involvement is not uncommon and is responsible for a poor prognosis.Disclosure of InterestsNone declared
Collapse
|
7
|
Cheze S, Quittet P, Adoue D, Viallard J, Sève P, Bonnotte B, Laribi K, Tardy S, Henique H, Hamidou M, Hacini M, Santagostino A, Leclerc-Teffahi S, Filipovics A, Brini F, Munier J, Malastesta A, Michel M. Étude observationnelle prospective sur les patients atteints de Purpura Thrombopénique Immunologique (PTI) traités par des agonisTEs des R-TPO (ARTPO): Eltrombopag (EPAG) et Romiplostim (ROMI) (Etude PEPITE). Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.10.270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
8
|
Moulis G, Comont T, Adoue D. New insights into the epidemiology of immune thrombocytopenia in adult patients: Impact for clinical practice. Rev Med Interne 2020; 42:11-15. [PMID: 32798089 DOI: 10.1016/j.revmed.2020.05.018] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2020] [Accepted: 05/26/2020] [Indexed: 12/28/2022]
Abstract
New insights into immune thrombocytopenia (ITP) epidemiology in adult patients highlight three main outcomes of morbidity and mortality: bleeding, infection and thrombosis. This review depicts current evidence about incidence and risk factors of bleeding, infection and thrombosis as well as predictors of chronicity, and shows how this assessment impacts the choice of ITP second-line treatment at the individual-level basis.
Collapse
Affiliation(s)
- G Moulis
- Service de Médecine Interne, CHU de Toulouse, France; UMR 1027 INSERM, Université de Toulouse, France; CIC 1436, CHU de Toulouse, France.
| | - T Comont
- Service de Médecine Interne, Institut Universitaire du Cancer de Toulouse- Oncopôle, France
| | - D Adoue
- Service de Médecine Interne, Institut Universitaire du Cancer de Toulouse- Oncopôle, France
| |
Collapse
|
9
|
Porel T, DE Almeida Chaves S, Adoue D, Astudillo L, Ribes D, Prévôt G, Gaches F, Michaud M, Alric L, Sailler L, Pugnet G. SAT0339 NERVOUS SYSTEM INVOLVEMENT IN SYSTEMIC SCLEROSIS: A COHORT STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.6142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Nervous system involvement is considered to be rare in systemic sclerosis (SSc). Its prevalence is highly variable in SSc cohort studies and its prognosis is not well established.Objectives:To determine the frequency, clinical characteristics, associations, and outcomes of different types of peripheral nervous system (PNS) and central nervous system (CNS) disease in a cohort of systemic sclerosis patients.Methods:We have carried out a retrospective observational study by systematically analyzing the medical records of patients diagnosed with SSc in Toulouse University Hospital and Ducuing Hospital, south west France. We included patients who met the following inclusion criteria: being over 18 years of age on diagnosis, meeting the ACR /EULAR 2013 classification criteria, being diagnosed after 01/01/1966 and before 31/12/2018, at least 12 months of follow-up. Patients were followed until 31/12/2019. Nervous system involvement associated with SSc was included when there was involvement on or after diagnosis and after exclusion of all other causes. Only symptomatic clinical involvement was included. Ischemic or hemorrhagic strokes were excluded. We calculated the incidence of CNS and/or PNS disease during the follow-up period per 1,000 person-years. Kaplan-Meier curves were plotted to determine the cumulative incidence of nervous system disease. We evaluated associated factors of CNS and/or PNS disease using multivariable Cox regression.Results:Of 447 SSc patients, 79.8% were female, 68 (15%) were diffuse cutaneous SSc, 342 (77%) were limited cutaneous SSc and 37 (8%) were sine scleroderma SSc. The mean ± SD age at diagnosis was 52.9 ± 14.3 years.During the study period, 82 (18%) patients experienced a PNS disease, 29 (6%) a CNS disease. The incidence was 28 per 1,000 patient-years of any nervous system disease, with 22 per 1,000 patient-years and 6 per 1,000 patient-years of PNS disease and CNS disease, respectively. The most frequent were carpal tunnel syndrome (63%) and polyneuropathies (12%) for PNS disease, and headache (45%) and seizures (10%) for CNS disease.Three significant independent associated factors with PNS disease occurrence were identified using multivariable Cox regression: BMI>23.1kg/m2(HR = 1.06 [1.01-1.12]), joint involvement (HR = 2.7 [1.3-5.5]), and an alteration in the left ventricular ejection fraction (HR = 3.8 [1.4-10.3]).Four significant independent associated factors with CNS disease occurrence were identified: age > 54 years (HR = 2.5 [1.1-6.0]), positive anti-PmScl testing (HR = 6.4 [1.5-28.2]), Caucasian origin (HR = 0.2 [0.1-0.5]) and hemoglobin < 12g/dl (HR = 0.2 [0.04-0.8]).Nervous system disease occurrence did not appear to have a negative impact on the survival of SSc patients (log-rank p=0.56).Conclusion:This study shows that specific nervous system disease in SSc is not uncommon and does not appear to increase mortality, but it could have an impact on functional prognosis and needs to be monitored.Disclosure of Interest:None declared
Collapse
|
10
|
Sokal A, De Nadai T, Comont T, Limal N, Michel M, Beyne-Rauzy O, Godeau B, Adoue D, Mahévas M, Moulis G. Purpura thrombopénique immunologique du sujet très âgé : particularités cliniques et de prise en charge. Résultats du registre prospectif multicentrique CARMEN-France. Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.10.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
11
|
Comont T, Brun N, Germain J, Dingremont C, Castel B, Arista S, Madaule S, Montané De La Roque P, Prudhomme L, Sailler L, Balardy L, Alric L, Gaches F, Lapeyre-Mestre M, Beyne-Rauzy O, Adoue D, Moulis G. Rentabilité diagnostique du myélogramme systématique chez les patients de plus de 60 ans au diagnostic de purpura thrombopénique immunologique pour rechercher une cause secondaire. Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.10.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
12
|
Comont T, Adoue D, Beyne-Rauzy O. Apport du dosage systématique de la ferritine et des gammaglobulines au diagnostic différentiel entre thrombopénie immunologique et maladie de Gaucher en phase initiale. Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.10.157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
13
|
Mourguet M, Chauveau D, Faguer S, Ruidavets J, Béjot Y, Ribes D, Huart A, Alric L, Balardy L, Astudillo L, Adoue D, Sailler L, Pugnet G. Increased ischemic stroke, acute coronary artery disease and mortality in patients with granulomatosis with polyangiitis and microscopic polyangiitis. J Autoimmun 2019; 96:134-141. [DOI: 10.1016/j.jaut.2018.09.004] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2018] [Revised: 09/09/2018] [Accepted: 09/12/2018] [Indexed: 01/19/2023]
|
14
|
Guille M, Comont T, Boumaza X, Cougoul P, Delavigne K, Albucher J, De Nadai T, Beyne-Rauzy O, Adoue D. Syndrome d’encéphalopathie postérieure réversible compliquant une hémoglobinurie paroxystique nocturne : une association exceptionnelle. Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.10.111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
15
|
Piel-Julian ML, Mahévas M, Germain J, Languille L, Comont T, Lapeyre-Mestre M, Payrastre B, Beyne-Rauzy O, Michel M, Godeau B, Adoue D, Moulis G. Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults. J Thromb Haemost 2018; 16:1830-1842. [PMID: 29978544 DOI: 10.1111/jth.14227] [Citation(s) in RCA: 61] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2018] [Accepted: 06/23/2018] [Indexed: 01/19/2023]
Abstract
Essentials Risk factors of bleeding in adult immune thrombocytopenia are not known. This multicenter study assessed risk factors of bleeding at immune thrombocytopenia onset. Platelet count thresholds associated with bleeding were < 20 × 109 L-1 and < 10 × 109 L-1 . Exposure to anticoagulants was a major risk factor of severe bleeding. SUMMARY Background The aim of this cross-sectional study was to assess risk factors for bleeding in immune thrombocytopenia (ITP) adults, including the determination of platelet count thresholds. Methods We selected all newly diagnosed ITP adults included in the Cytopénies Auto-immunes Registre Midi-PyrénéEN (CARMEN) register and at the French referral center for autoimmune cytopenias. The frequencies of any bleeding, mucosal bleeding and severe bleeding (gastrointestinal, intracranial, or macroscopic hematuria) at ITP onset were assessed. Platelet count thresholds were assessed by the use of receiver operating characteristic curves. All potential risk factors were included in logistic regression models. Results Among the 302 patients, the frequencies of any, mucosal and severe bleeding were 57.9%, 30.1%, and 6.6%, respectively. The best discriminant threshold of platelet count for any bleeding was 20 × 109 L-1 . In multivariate analysis, factors associated with any bleeding were platelet count (< 10 × 109 L-1 versus ≥ 20 × 109 L-1 , odds ratio [OR] 48.2, 95% confidence interval [CI] 20.0-116.3; between 10 × 109 L-1 and 19 × 109 L-1 versus ≥ 20 × 109 L-1 , OR 5.2, 95% CI 2.3-11.6), female sex (OR 2.6, 95% CI 1.3-5.0), and exposure to non-steroidal anti-inflammatory drugs (NSAIDs) (OR 4.8, 95% CI 1.1-20.7). A low platelet count was also the main risk factor for mucosal bleeding. Exposure to anticoagulant drugs was associated with severe bleeding (OR 4.3, 95% CI 1.3-14.1). Conclusions Platelet counts of < 20 × 109 L-1 and < 10 × 109 L-1 were thresholds for major increased risks of any and mucosal bleeding. Platelet count, female sex and exposure to NSAIDs should be considered for assessment of the risk of any bleeding. Exposure to anticoagulant drugs was a major risk factor for severe bleeding.
Collapse
Affiliation(s)
- M-L Piel-Julian
- Service de Médecine Interne, Salle Le Tallec, Centre Hospitalier Universitaire de Toulouse-Purpan, Toulouse, France
| | - M Mahévas
- Service de Médecine Interne, CHU Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Centre de Référence des Cytopénies Auto-Immunes de l'adulte, Université Paris-Est-Créteil, Créteil, France
| | - J Germain
- Centre d'Investigation Clinique 1436, Axe Pharmacoépidémiologie, Centre Hospitalier Universitaire de Toulouse-Purpan, Toulouse, France
| | - L Languille
- Service de Médecine Interne, CHU Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Centre de Référence des Cytopénies Auto-Immunes de l'adulte, Université Paris-Est-Créteil, Créteil, France
| | - T Comont
- Service de Médecine Interne, Institut Universitaire du Cancer de Toulouse - Oncopôle, Toulouse, France
| | - M Lapeyre-Mestre
- Centre d'Investigation Clinique 1436, Axe Pharmacoépidémiologie, Centre Hospitalier Universitaire de Toulouse-Purpan, Toulouse, France
- UMR 1027, INSERM-Université de Toulouse, Toulouse, France
- Service de Pharmacologie Médicale et Clinique, CHU de Toulouse, Toulouse, France
| | - B Payrastre
- Inserm U1048 (I2MC), CHU de Toulouse and Université Toulouse III, Toulouse, France
- Laboratoire d'Hématologie, CHU de Toulouse, Toulouse, France
| | - O Beyne-Rauzy
- Service de Médecine Interne, Institut Universitaire du Cancer de Toulouse - Oncopôle, Toulouse, France
| | - M Michel
- Service de Médecine Interne, CHU Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Centre de Référence des Cytopénies Auto-Immunes de l'adulte, Université Paris-Est-Créteil, Créteil, France
| | - B Godeau
- Service de Médecine Interne, CHU Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Centre de Référence des Cytopénies Auto-Immunes de l'adulte, Université Paris-Est-Créteil, Créteil, France
| | - D Adoue
- Service de Médecine Interne, Institut Universitaire du Cancer de Toulouse - Oncopôle, Toulouse, France
| | - G Moulis
- Service de Médecine Interne, Salle Le Tallec, Centre Hospitalier Universitaire de Toulouse-Purpan, Toulouse, France
- Centre d'Investigation Clinique 1436, Axe Pharmacoépidémiologie, Centre Hospitalier Universitaire de Toulouse-Purpan, Toulouse, France
- UMR 1027, INSERM-Université de Toulouse, Toulouse, France
| |
Collapse
|
16
|
Mourguet M, Chauveau D, Ruidavets J, Bejot Y, Ribes D, Huart A, Alric L, Balardy L, Astudillo L, Adoue D, Sailler L, Pugnet G. Étude du risque cardiovasculaire chez les patients atteints de vascularites associées aux ANCA. Incidence, mortalité et facteurs prédictifs. Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.10.297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
17
|
Comont T, Cougoul P, Delavigne K, Ollier S, Adoue D, Beyne-rauzy O. Thrombopénie immunologique en phase aiguë au cours d’une crise vaso-occlusive chez une patiente drépanocytaire : une prise en charge complexe. Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.10.224] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
18
|
Piel-Julian M, Mahevas M, Comont T, Brun N, Dingremont C, Castel B, Lapeyre-Mestre M, Beyne-rauzy O, Adoue D, Godeau B, Moulis G. Seuil de numération plaquettaire et autres facteurs de risque hémorragique au diagnostic de thrombopénie immunologique de l’adulte. Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.10.329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
19
|
Paricaud K, Pugnet G, Astudillo L, Moulis G, Arlet P, Alric L, Thiercelin-Legrand M, Adoue D, Balardy L, Constantin A, Gaches F, Sailler L. Évolution à 5 ans au cours de l’artérite cellule géante : des indications pour guider la prescription de tocilizumab ? Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.10.291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
20
|
Moulis G, Lapeyre-Mestre M, Adoue D, Sailler L. Épidémiologie et pharmacoépidémiologie du purpura thrombopénique immunologique. Rev Med Interne 2017; 38:444-449. [DOI: 10.1016/j.revmed.2016.12.016] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2016] [Revised: 10/04/2016] [Accepted: 12/22/2016] [Indexed: 02/06/2023]
|
21
|
De Almeida Chaves S, Comont T, Dufranc E, Laclau S, Nicolai V, Delavigne K, Cougoul P, Ollier S, Adoue D, Beyne-rauzy O. Association entre thrombopénie immunologique et thrombose : à propos de 5 cas. Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.03.152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
22
|
Fayand A, Kone-Paut I, Hentgen V, Stankovic K, Adoue D, Perlat A, Quartier P, Bader-Meunier B, Dhôte R, Amselem S, Grateau G, Georgin-Lavialle S. Le syndrome PFAPA (ou syndrome de Marshall) existe-t-il chez les adultes ? À propos de 20 cas. Rev Med Interne 2016. [DOI: 10.1016/j.revmed.2016.10.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
23
|
Essilini A, Comont T, Germain J, Brun N, Dingremont C, Castel B, Arista S, Madaule S, Sailler L, Beyne-rauzy O, Adoue D, Moulis G. Intérêt d’initier la corticothérapie à dose conventionnelle par méthylprednisolone intraveineuse dans le purpura thrombopénique immunologique nouvellement diagnostiqué de l’adulte. Rev Med Interne 2016. [DOI: 10.1016/j.revmed.2016.10.131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
24
|
Laustriat G, Degboe Y, Ruyssen-Witrand A, Constantin A, Barnetche T, Adoue D, Cantagrel A. AB0598 Does The Presence of Anti-Citrullinated Protein Antibodies Change The Presentation of Systemic Sclerosis? Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.2187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
25
|
Mathian A, Arnaud L, Adoue D, Agard C, Bader-Meunier B, Baudouin V, Belizna C, Bonnotte B, Boumedine F, Chaib A, Chauchard M, Chiche L, Daugas E, Ghali A, Gobert P, Gondran G, Guettrot-Imbert G, Hachulla E, Hamidou M, Haroche J, Hervier B, Hummel A, Jourde-Chiche N, Korganow AS, Kwon T, Le Guern V, Le Quellec A, Limal N, Magy-Bertrand N, Marianetti-Guingel P, Martin T, Martin Silva N, Meyer O, Miyara M, Morell-Dubois S, Ninet J, Pennaforte JL, Polomat K, Pourrat J, Queyrel V, Raymond I, Remy P, Sacre K, Sibilia J, Viallard JF, Viau Brabant A, Hanslik T, Amoura Z. Prévention des infections au cours du lupus systémique chez l’adulte et l’adolescent : élaboration de recommandations pour la pratique clinique, à partir d’une analyse de la littérature et de l’avis d’experts. Rev Med Interne 2016; 37:307-20. [DOI: 10.1016/j.revmed.2016.01.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2015] [Revised: 01/03/2016] [Accepted: 01/05/2016] [Indexed: 12/21/2022]
|
26
|
Comont T, Pourrat J, Luxembourger C, Talibart M, Adoue D, Beyne-rauzy O. Traitement d’un syndrome périodique lié à la cryopyrine (CAPS) : efficacité de l’anakinra en cas d’échappement thérapeutique au canakinumab. Rev Med Interne 2015. [DOI: 10.1016/j.revmed.2015.10.208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
27
|
Moulis G, Comont T, Germain J, Brun N, Dingremont C, Castel B, Arista S, Madaule S, Prudhomme L, Godeau B, Beyne-rauzy O, Adoue D. Épidémiologie clinique et traitement de première ligne dans la thrombopénie immunologique. Résultats du registre CARMEN. Rev Med Interne 2015. [DOI: 10.1016/j.revmed.2015.10.337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
28
|
Mezaache S, Comont T, Germain J, Montastruc F, Brun N, Dingremont C, Castel B, Arista S, Godeau B, Beyne-rauzy O, Adoue D, Moulis G. Incidence des effets indésirables des traitements médicamenteux de la thrombopénie immunologique de l’adulte. Résultats du registre CARMEN. Rev Med Interne 2015. [DOI: 10.1016/j.revmed.2015.10.295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
29
|
Moulis G, Comont T, Brun N, Dingremont C, Castel B, Arista S, Madaule S, Montané De La Roque P, Prudhomme L, Lapeyre-Mestre M, Beyne-rauzy O, Adoue D. Prescription et rentabilité diagnostique du bilan paraclinique au diagnostic de thrombopénie immunologique. Résultats du registre CARMEN. Rev Med Interne 2015. [DOI: 10.1016/j.revmed.2015.03.285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
30
|
Gaudré N, Moulis G, Fernandez S, Azema O, Cougoul P, Beyne-rauzy O, Adoue D. Tous les patients se présentant aux urgences pour crise vaso-occlusive sont-ils drépanocytaires ? Étude rétrospective au CHU de Toulouse. Rev Med Interne 2015. [DOI: 10.1016/j.revmed.2015.03.320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
31
|
Brechemier D, Comont T, Bertoli S, Dutertre M, Recher C, Adoue D, Beyne-Rauzy O. 91 IRON CHELATION AND VITAMIN-D3 IN COMBINATION WITH AZACITIDINE IMPROVES TREATMENT RESPONSE IN 19 HIGH RISK MYELODYSPLASTIC SYNDROMES AFTER AZACITIDINE FAILURE. Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30092-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
32
|
Brechemier D, Comont T, Bertoli S, Lozano S, Gerard S, Adoue D, Lauwers-Cances V, Beyne-Rauzy O. 92 IMPACT OF COMORBIDITIES AND GERIATRIC ASSESSMENT IN HIGH RISK MYELODYSPLASTIC SYNDROMES OVER 75 YEARS TREATED WITH AZACITIDINE. Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30093-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
33
|
Arnaud L, Mathian A, Adoue D, Bader-Meunier B, Baudouin V, Belizna C, Bonnotte B, Boumedine F, Chaib A, Chauchard M, Chiche L, Daugas E, Ghali A, Gobert P, Gondran G, Guettrot-Imbert G, Hachulla E, Hamidou M, Haroche J, Hervier B, Hummel A, Jourde-Chiche N, Korganow AS, Kwon T, Le Guern V, Le Quellec A, Limal N, Magy-Bertrand N, Marianetti-Guingel P, Martin T, Martin Silva N, Meyer O, Miyara M, Morell-Dubois S, Ninet J, Papo T, Pennaforte JL, Polomat K, Pourrat J, Queyrel V, Raymond I, Remy P, Sacre K, Schmidt J, Sibilia J, Viallard JF, Viau Brabant A, Wahl D, Bruckert E, Amoura Z. [Screening and management of cardiovascular risk factors in systemic lupus erythematosus: Recommendations for clinical practice based on the literature and expert opinion]. Rev Med Interne 2014; 36:372-80. [PMID: 25455954 DOI: 10.1016/j.revmed.2014.10.009] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2013] [Revised: 04/17/2014] [Accepted: 10/13/2014] [Indexed: 11/28/2022]
Abstract
PURPOSE To develop French recommendations about screening and management of cardiovascular risk factors in systemic lupus erythematosus (SLE). METHODS Thirty-nine experts qualified in internal medicine, rheumatology and nephrology have selected recommendations from a list developed based on evidence from the literature. For each recommendation, the level of evidence and the level of agreement among the experts were specified. RESULTS Experts recommended an annual screening of cardiovascular risk factors in SLE. Statins should be prescribed for primary prevention in SLE patients based on the level of LDL-cholesterol and the number of cardiovascular risk factors, considering SLE as an additional risk factor. For secondary prevention, experts have agreed on an LDL-cholesterol target of <0.7 g/L. Hypertension should be managed according to the 2013 European guidelines, using renin-angiotensin system blockers as first line agents in case of renal involvement. Aspirin can be prescribed in patients with high cardiovascular risk or with antiphospholipid antibodies. CONCLUSION These recommendations about the screening and management of cardiovascular risk factors in SLE can be expected to improve clinical practice uniformity and, in the longer term, to optimize the management of SLE patients.
Collapse
Affiliation(s)
- L Arnaud
- Service de médecine interne 2, Centre national de référence du lupus systémique, groupe hospitalier Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France; Sorbonne universités, UPMC université Paris 06, 75013 Paris, France.
| | - A Mathian
- Service de médecine interne 2, Centre national de référence du lupus systémique, groupe hospitalier Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France; Sorbonne universités, UPMC université Paris 06, 75013 Paris, France
| | - D Adoue
- Service de médecine interne et immunopathologie clinique, hôpital Purpan, Toulouse, France
| | - B Bader-Meunier
- Service d'immunologie et rhumatologie pédiatrique, centre de référence des maladies rares rhumatologiques et inflammatoires pédiatriques (CERHUMIP), hôpital Necker, Paris, France
| | - V Baudouin
- Service de néphrologie pédiatrique, hôpital Robert-Debré, Paris, France
| | - C Belizna
- Service de médecine interne, CHU d'Angers, Angers, France
| | - B Bonnotte
- Service de médecine interne et immunologie clinique, CHU Bocage, Dijon, France
| | - F Boumedine
- Service de médecine interne 2, Centre national de référence du lupus systémique, groupe hospitalier Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France
| | - A Chaib
- Service de médecine interne 2, Centre national de référence du lupus systémique, groupe hospitalier Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France
| | - M Chauchard
- Service de médecine interne, hôpital Bichat, Claude-Bernard, Paris, France
| | - L Chiche
- Service de médecine interne, hôpital de la Conception, Marseille, France
| | - E Daugas
- Service de néphrologie, hôpital Bichat, Paris, France
| | - A Ghali
- Service de médecine interne, CHU d'Angers, Angers, France
| | - P Gobert
- Service de médecine interne et néphrologie, centre hospitalier d'Avignon, Avignon, France
| | - G Gondran
- Service de médecine interne A, hôpital Dupuytren, CHU de Limoges, Limoges, France
| | - G Guettrot-Imbert
- Service de médecine interne, hôpital Gabriel-Montpied, CHU, Clermont-Ferrand, France
| | - E Hachulla
- Service de médecine interne, hôpital Claude-Huriez, CHRU de Lille, Lille, France
| | - M Hamidou
- Service de médecine interne, Nantes, France
| | - J Haroche
- Service de médecine interne 2, Centre national de référence du lupus systémique, groupe hospitalier Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France; Sorbonne universités, UPMC université Paris 06, 75013 Paris, France
| | - B Hervier
- Service de médecine interne 2, Centre national de référence du lupus systémique, groupe hospitalier Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France
| | - A Hummel
- Service de néphrologie adulte, hôpital Necker, Paris, France
| | - N Jourde-Chiche
- Service de néphrologie, hôpital de la Conception, Marseille, France
| | - A-S Korganow
- Service d'immunologie clinique, hôpital civil, CHU de Strasbourg, Strasbourg, France
| | - T Kwon
- Service de néphrologie pédiatrique, hôpital Robert-Debré, Paris, France
| | - V Le Guern
- Service de médecine interne, centre de référence maladies systémiques et auto-immunes rares, sclérodermies, vascularites, groupe hospitalier Cochin, Paris, France
| | - A Le Quellec
- Service de médecine interne A, hôpital Saint-Éloi, Montpellier, France
| | - N Limal
- Service de médecine interne, CHU Henri-Mondor, Créteil, France
| | - N Magy-Bertrand
- Service de médecine interne, CHU Jean-Minjoz, Besançon, France
| | | | - T Martin
- Service d'immunologie clinique, hôpital civil, CHU de Strasbourg, Strasbourg, France
| | | | - O Meyer
- Service de rhumatologie, hôpital Bichat-Claude-Bernard, Paris, France
| | - M Miyara
- Service de médecine interne 2, Centre national de référence du lupus systémique, groupe hospitalier Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France
| | - S Morell-Dubois
- Service de médecine interne, hôpital Claude-Huriez, CHRU de Lille, Lille, France
| | - J Ninet
- Service de médecine interne, hôpital Édouard-Herriot, CHRU de Lyon, Lyon, France
| | - T Papo
- Service de médecine interne, hôpital Bichat, Claude-Bernard, Paris, France
| | - J-L Pennaforte
- Service de médecine interne, CHU de Reims, Reims, France
| | - K Polomat
- Service de médecine interne 5D, CHU de Martinique, Fort-de-France, Martinique
| | - J Pourrat
- Service de néphrologie, hôpital Rangueil, CHU, Toulouse, France
| | - V Queyrel
- Service de médecine interne, hôpital de l'Archet, Nice, France
| | - I Raymond
- Service de médecine interne et maladies infectieuses, hôpital Haut-Lévêque, centre François-Magendie, Pessac, France
| | - P Remy
- Service de néphrologie, groupe hospitalier Henri-Mondor, Créteil, France
| | - K Sacre
- Service de médecine interne, hôpital Bichat, Claude-Bernard, Paris, France
| | - J Schmidt
- Service de médecine interne, CHU Nord, Amiens, France
| | - J Sibilia
- Service de rhumatologie, CHU Hautepierre, Strasbourg, France
| | - J-F Viallard
- Service de médecine interne et maladies infectieuses, hôpital Haut-Lévêque, centre François-Magendie, Pessac, France
| | - A Viau Brabant
- Service de médecine interne, CHU de Reims, Reims, France
| | - D Wahl
- Inserm U 1116, service de médecine vasculaire, département de médecine interne, institut lorrain du cœur et des vaisseaux Louis-Mathieu, centre de compétence régional des maladies systémiques et auto-immunes rares, CHU de Nancy, université de Lorraine, Vandœuvre-lès-Nancy, France
| | - E Bruckert
- Service d'endocrinologie, métabolisme et prévention cardiovasculaire, hôpital Pitié-Salpêtrière, AP-HP, 75013 Paris, France
| | - Z Amoura
- Service de médecine interne 2, Centre national de référence du lupus systémique, groupe hospitalier Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France; Sorbonne universités, UPMC université Paris 06, 75013 Paris, France
| | | |
Collapse
|
34
|
Cougoul P, Gauthier M, Fogel O, Ysebaert L, Alric L, Adoue D, Beyne-Rauzy O. Troubles du rythme supraventriculaires : une complication sous-estimée de la surcharge en fer chez les patients thalassémiques ? Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.03.133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
35
|
Moulis G, Lapeyre-Mestre M, Adoue D, Sailler L. Incidence des manifestations hémorragiques graves au diagnostic de thrombopénie immunologique en France. Résultats à partir de l’étude FAITH (French Adult Immune Thrombocytopenia: a pHarmacoepidemiological study). Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.03.106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
36
|
Moulis G, Lapeyre-Mestre M, Arnaud L, Adoue D, Sailler L. Incidence de la thrombopénie immunologique en France : un gradient nord-sud. Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.03.105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
37
|
Khellaf M, Fain O, Viallard J, Cheze S, Hamidou M, Audia S, Schleinitz N, Le Guenno G, Lambotte O, Adoue D, Michel M, Godeau B. Tolérance et efficacité du Rituximab chez les patients adultes atteints de purpura thrombopénique immuologique : résultats après un an de suivi chez 252 patients inclus dans le registre prospectif français PTI-Ritux. Rev Med Interne 2013. [DOI: 10.1016/j.revmed.2013.10.101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
38
|
Moulis G, Palmaro A, Adoue D, Lapeyre-Mestre M, Sailler L. Incidence de la thrombopénie immunologique en France. Résultats à partir de la cohorte FAITH. Rev Med Interne 2013. [DOI: 10.1016/j.revmed.2013.10.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
39
|
Moulis G, Sailler L, Sommet A, Lapeyre-Mestre M, Recher C, Alric L, Arlet P, Adoue D. Prophylaxie infectieuse chez les patients adultes exposés au rituximab ou à la splénectomie pour purpura thrombopénique immunologique primaire. Rev Med Interne 2012. [DOI: 10.1016/j.revmed.2012.10.153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
40
|
Moeglin J, Comont T, Delavigne K, Adoue D, Beyne-Rauzy O. L’érythroblastopénie une cause rare d’anémie au cours du lupus, d’étiologie variée et de pronostic favorable. Rev Med Interne 2012. [DOI: 10.1016/j.revmed.2012.10.157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
41
|
Fazal Janot J, Cougoul P, Comont T, Sartor A, Bloom D, Ollier S, Beyne-Rauzy O, Parant O, Adoue D. Drépanocytose et grossesse : l’expérience du CHU de Toulouse. Rev Med Interne 2012. [DOI: 10.1016/j.revmed.2012.03.341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
42
|
Pasquali JL, Hachulla E, Bletry O, Adoue D, Petri M, Cerva R, Kleoudis C, Zhong Z, Roth D, Van Vollenhoven R. Facteurs associés au bénéfice du traitement par belimumab : résultats des études de phase 3 chez les patients atteints de lupus systémique. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.10.296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
43
|
Adoue D, Navarra S, Petri M, Gallacher A, Guzman R, Furie R, Thomas M, Zamani O, Levy R, Van Vollenhoven R, Cerva R, Wallace D. Profil de tolérance du bélimumab, inhibiteur de BLyS, chez des patients atteints de lupus systémique (LS) actif dans les essais cliniques de phase 2 et 3. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.10.214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
44
|
Bletry O, Strand V, Cooper S, Zhong Z, Dennis G, Adoue D, Pasquali JL, Hachulla E. Amélioration de la fatigue et la qualité de vie à 52 semaines chez les patients atteints de lupus systémique répondeurs dans les essais cliniques de phase 3 du bélimumab. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.10.215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
45
|
Comont T, Khalifa J, Lelièvre L, Demas V, Hébrard AL, Cougoul P, Ollier S, Adoue D, Beyne-Rauzy O. Risque thrombotique au cours des myélodysplasies avec thrombocytose : la cytogénétique est un facteur de risque potentiel. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.10.397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
46
|
Hachulla E, Adoue D, Bletry O, Pasquali JL, Furie RA, Freimuth W, Petri M. Évaluation clinico-biologique des patients répondeurs selon le SRI (SLE responder index) dans les essais cliniques de phase III portant sur le bélimumab. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.10.272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
47
|
Grimaldi-Bensouda L, Michel M, Viallard JF, Adoue D, Magy-Bertrand N, Khellaf M, Morin AS, Leighton P, Aubrun E, Alperovitch A, Abenhaim L, Godeau B. La vaccination est-elle associée au risque de survenue d’un purpura thrombopénique immunologique chez l’adulte ? Résultat d’une étude prospective multicentrique cas-témoins utilisant le registre PTI-PGRx. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.10.374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
48
|
Cougoul P, Cassagne M, Bellière J, Modesto-Segonds A, Courtellemont C, Huart A, Adoue D. Une uvéite de cause peu fréquente : TINU syndrome. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.03.265] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
49
|
Bréchemier D, Bellière J, Dutertre M, Ollier S, Cougoul P, Beyne-Rauzy O, Adoue D. Infarctus splénique massif survenant dans le tableau initial d́une maladie de Wegener. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.03.245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
50
|
Comont T, Gaudre N, Moeglin J, Cougoul P, Leveneur Y, Adoue D, Récher C, Beyne-Rauzy O. 163 Extra-medullary localization in high risk myelodysplastic syndromes: A new modality of relapse after therapy. Leuk Res 2011. [DOI: 10.1016/s0145-2126(11)70165-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|